Phase II Study of Yttrium-90-Ibritumomab Tiuxetan as Part of Reduced-Intensity Conditioning (with Melphalan, Fludarabine ± Thiotepa) for Allogeneic Transplantation in Relapsed or Refractory Aggressive B Cell Lymphoma: A GELTAMO Trial
Titel:
Phase II Study of Yttrium-90-Ibritumomab Tiuxetan as Part of Reduced-Intensity Conditioning (with Melphalan, Fludarabine ± Thiotepa) for Allogeneic Transplantation in Relapsed or Refractory Aggressive B Cell Lymphoma: A GELTAMO Trial
Auteur:
Cabrero, Monica Martin, Alejandro Briones, Javier Gayoso, Jorge Jarque, Isidro López, Javier Grande, Carlos Heras, Inmaculada Arranz, Reyes Bernal, Teresa Perez-Lopez, Estefania López-Godino, Oriana Conde, Eulogio Caballero, Dolores
Verschenen in:
Biology of blood and marrow transplantation
Paginering:
Jaargang 23 (2017) nr. 1 pagina's 53-59
Jaar:
2017
Inhoud:
Uitgever:
The American Society for Blood and Marrow Transplantation